A phase II study of GM-CSF and rIFN-γ1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

Gynecologic Oncology

Volumn 113, Issue 2, 2009, Pages 210-215

  Schmeler, Kathleen M ^a   Vadhan Raj, Saroj ^a   Ramirez, Pedro T ^a   Apte, Sachin M ^b   Cohen, Lorenzo ^a   Bassett, Roland L ^a   Iyer, Revathy B ^a   Wolf, Judith K ^a   Levenback, Charles L ^a   Gershenson, David M ^a   Freedman, Ralph S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Carboplatin; GM CSF; Immunotherapy; Interferon; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GAMMA1B INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PACLITAXEL; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ANXIETY; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEPRESSION; DESENSITIZATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA; VOMITING;

ADULT; AGED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-GAMMA, RECOMBINANT; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; QUALITY OF LIFE;

EID: 63749113820     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.02.007     Document Type: Article

References (33)

1. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9 (1991) 389-393
2. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
3. Gonzalez-Martin A.J., Calvo E., Bover I., Rubio M.J., Arcusa A., Casado A., et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann. Oncol. 16 (2005) 749-755
4. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24 (2006) 4699-4707
5. Strauss H.G., Henze A., Teichmann A., Karbe I., Baumgart A., Thomssen C., et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol. Oncol. 104 (2007) 612-616
6. Ferrero J.M., Weber B., Geay J.F., Lepille D., Orfeuvre H., Combe M., et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann. Oncol. 18 (2007) 263-268
7. Triozzi P.L., Tucker F., Benzies T., and Balcerzak S.P. Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor. Bone Marrow Transplant 18 (1996) 47-52
8. Allavena P., Peccatori F., Maggioni D., Erroi A., Sironi M., Colombo N., et al. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res. 50 (1990) 7318-7323
9. Grabstein K.H., Urdal D.L., Tushinski R.J., Mochizuki D.Y., Price V.L., Cantrell M.A., et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232 (1986) 506-508
10. Spitler L.E., Grossbard M.L., Ernstoff M.S., Silver G., Jacobs M., Hayes F.A., et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 18 (2000) 1614-1621
11. Buter J., and Pinedo H.M. Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored. Curr. Oncol. Rep. 5 (2003) 171-176
12. Pujade-Lauraine E., Guastalla J.P., Colombo N., Devillier P., Francois E., Fumoleau P., et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J. Clin. Oncol. 14 (1996) 343-350
13. Windbichler G.H., Hausmaninger H., Stummvoll W., Graf A.H., Kainz C., Lahodny J., et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer 82 (2000) 1138-1144
14. Marth C., Windbichler G.H., Hausmaninger H., Petru E., Estermann K., Pelzer A., et al. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int. J. Gynecol. Cancer 16 (2006) 1522-1528
15. Alberts D.S., Marth C., Alvarez R.D., Johnson G., Bidzinski M., Kardatzke D.R., et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol. Oncol. 109 (2008) 174-181
16. Vadhan-Raj S., Broxmeyer H.E., Hittelman W.N., Papadopoulos N.E., Chawla S.P., Fenoglio C., et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J. Clin. Oncol. 10 (1992) 1266-1277
17. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7 (1989) 1748-1756
18. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
19. Markman M., Markman J., Webster K., Zanotti K., Kulp B., Peterson G., et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J. Clin. Oncol. 22 (2004) 3120-3125
20. Bast R.C., Thigpen J.T., Arbuck S.G., Basen-Engquist K., Burke L.B., Freedman R., et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol. Oncol. 107 (2007) 173-176
21. Trotti A., Byhardt R., Stetz J., Gwede C., Corn B., Fu K., et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 47 (2000) 13-47
22. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales, Center on Outcomes, Research and Education (CORE): Evanston Northwestern Healthcare and Northwestern University, 1997 (1997)
23. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Linn E., Bonomi A., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol. 11 (1993) 570-579
24. Motzer R.J., Murphy B.A., Bacik J., Schwartz L.H., Nanus D.M., Mariani T., et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18 (2000) 2972-2980
25. Cella D., Zagari M.J., Vandoros C., Gagnon D.D., Hurtz H.J., and Nortier J.W. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J. Clin. Oncol. 21 (2003) 366-373
26. Melichar B., Savary C.A., Patenia R., Templin S., Melicharova K., and Freedman R.S. Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int. J. Gynecol. Cancer 13 (2003) 435-443
27. Apte S.M., Vadhan-Raj S., Cohen L., Bassett R.L., Gordon I.O., Levenback C.F., et al. Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. J. Transplant. Med. 4 (2006) 16
28. Stavenhagen J.B., Gorlatov S., Tuaillon N., Rankin C.T., Li H., Burke S., et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res. 67 (2007) 8882-8890
29. Simon R., Wittes R.E., and Ellenberg S.S. Randomized phase II clinical trials. Cancer Treat Rep. 69 (1985) 1375-1381
30. Eisenhauer E.A., Vermorken J.B., and van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8 (1997) 963-968 [see comments]
31. Markman M., Kennedy A., Webster K., Elson P., Peterson G., Kulp B., et al. Clinical features of hypersensitivity reactions to carboplatin. J. Clin. Oncol. 17 (1999) 1141
32. Polyzos A., Tsavaris N., Kosmas C., Arnaouti T., Kalahanis N., Tsigris C., et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61 (2001) 129-133
33. Navo M., Kunthur A., Badell M.L., Coffer II L.W., Markman M., Brown J., et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol. Oncol. 103 (2006) 608-613